Workstream 1: Open access, 24 July 2017
|Ideally, pharma would publish in journals with gold open access, Creative Commons Attribution (CC-BY) licence and no embargo.
|We propose to develop a joint statement/letter.
|Publishers should not treat pharma and academia differently; some journals do not allow pharma gold open access, even with a payment.
|Outline the rationale for gold open access to be the standard, regardless of who funded the research.
|We need to talk directly with publishers and educate authors to drive change.
|Develop a toolkit to educate stakeholders from pharma, publishers and academia.
|We need an open access value proposition for pharma.
|Call for collaboration with organizations that have similar goals to ours.
Workstream 2: ORCID, CRediT and Convey, 28 July 2017
|ORCID is well established in the academic world, but we need to learn about ORCID’s value specifically for pharma.
|GSK Vaccines to report in September on their adoption of ORCID.
Ask Envision to integrate ORCID into Datavision.
|We need to learn more about CRediT, Convey and Publons, and assess their value to pharma.
|Learn more about Convey from an invited speaker at the next meeting.
Workstream 3: Preprints and post-publication peer review, 26 July 2017
|Preprints can increase speed and transparency, but the legal implications of the use of preprints for clinical research are unknown.
|Individual companies to discuss with their in‑house legal teams.
Oxford PharmaGenesis to approach regulators.
|F1000Research’s post-publication peer review platform offers additional advantages to pharma, including limiting research waste and the ability to track usage with metrics.
|Debrief from Liz Allen’s meeting with Lise Baltzer about F1000Research and Shailesh Desai’s conversation with Chris Rains about Shire’s interest in the model.
|Learn more about Declaration on Research Assessment (DORA).
Workstream 4: Layered publication platforms, 27 July 2017
|The pharma perspective is of key importance.
|Confirm buy-in from a broader group of pharma.
|No single model offers a complete answer.
|Present Crossref again for those who missed it.
|There is no consensus on how a layered platform should be structured and run.
|Develop a straw-man proposal on the ideal layered publication model.